Effectiveness of Calcium Channel Blockade for OP and Carbamate Pesticide Poisoning

Last updated: February 27, 2025
Sponsor: University of Edinburgh
Overall Status: Active - Not Recruiting

Phase

3

Condition

N/A

Treatment

Nimodipine

Magnesium Sulfate

Clinical Study ID

NCT03925025
AC19003
  • Ages > 16
  • All Genders

Study Summary

This study evaluates whether the addition of intravenous magnesium sulphate or nimodipine to standard therapy (supportive care plus for all patients atropine and, for OP insecticide poisoned patients, pralidoxime) benefits patients after acute anticholinesterase self-poisoning with OP or carbamate insecticides.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients aged 16 years or older with suspected OP or carbamate insecticideself-poisoning admitted to medical wards with the cholinergic toxidrome requiringatropine.

  • Diagnosis will be made on the basis of the cholinergic toxidrome clinical features (eg. small/pinpoint pupils, bronchorrhoea, sweating) or on the history of atropineadministration with beneficial effect. The insecticide involved will be identifiedwhere possible from the history, the bottle brought in by the patient or relative,the patient/relative identifying the pesticide on a chart showing all locallyavailable pesticides, and/or relatives sending a photo of the bottle by eg.WhatsApp.

  • Patients who ingest combination products containing OP or carbamate insecticideswill also be included.

  • Inhibited blood cholinesterase activity as shown by routine clinical bedside test

Exclusion

Exclusion Criteria:

  • Children aged <16 years.

  • Patients who do not require atropine and have not had it prior to presentationduring this episode.

  • Normal blood cholinesterase activity

  • Self-reported known pregnancy (as per South Asian practice, no attempt will be madeto formally test for pregnancy in the patients due to the issue of confidentialityin the acute care situation in these hospitals and the social consequences of anunexpected positive response)

  • Known occupational and homicidal poisoning

  • Past medical history of severely impaired renal function

  • Hypersensitivity to magnesium and its salts

  • Patients who have had a myocardial infarction or unstable angina in the last month

  • Patients with traumatic subarachnoid haemorrhage

  • Lack of informed consent (unaccompanied unconscious patients and others)

Study Design

Total Participants: 3243
Treatment Group(s): 2
Primary Treatment: Nimodipine
Phase: 3
Study Start date:
June 11, 2020
Estimated Completion Date:
April 30, 2025

Connect with a study center

  • Rajshahi Medical College Hospital

    Rājshāhi, Rajshahi 6100
    Bangladesh

    Site Not Available

  • Shaheed Ziaur Rahman Medical College

    Bogra, Silimpur 5800
    Bangladesh

    Site Not Available

  • Chattogram Medical College Hospital

    Chittagong, 4203
    Bangladesh

    Site Not Available

  • Jashore Medical College Hospital

    Jessore,
    Bangladesh

    Site Not Available

  • Khulna Medical College Hospital

    Khulna,
    Bangladesh

    Site Not Available

  • Rangpur Medical College Hospital

    Rangpur,
    Bangladesh

    Site Not Available

  • Sylhet MAG Osmani Medical College

    Sylhet, 3100
    Bangladesh

    Active - Recruiting

  • Sylhet MAG Osmani Medical College Hospital

    Sylhet,
    Bangladesh

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.